Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pragmatic Randomised, Trial Evaluating an Endocrine Therapy Dose-frequency Escalation Strategy and Its Effects on Tolerability and Compliance (REaCT-TEMPO)

NCT05754528 is registered in ClinicalTrials.gov with Ottawa Hospital Research Institute as lead sponsor.

NCT NCT05754528
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05754528 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pragmatic Randomised, Trial Evaluating an Endocrine Therapy Dose-frequency Escalation Strategy and Its Effects on Tolerability and Compliance (REaCT-TEMPO)
Lead sponsor
Ottawa Hospital Research Institute
Phase
Phase 4
Overall status
Active, not recruiting
Start date
July 28, 2023
Completion date
February 28, 2030
Enrollment
240 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer